+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Soliris"

From
SOLIRIS Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

SOLIRIS Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
From
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Soliris is a brand of drug used to treat rare, life-threatening immune disorders. It is a monoclonal antibody that works by blocking the activity of certain proteins in the body that can cause the immune system to attack healthy cells. It is used to treat two conditions: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is the only approved treatment for these conditions and is considered a breakthrough therapy. Soliris is a very expensive drug, with a high cost of production and distribution. It is typically administered intravenously in a hospital setting, and the cost of treatment can be prohibitive for many patients. Despite this, Soliris has become a major player in the immune disorders drugs market, due to its effectiveness in treating these rare conditions. Companies in the Soliris market include Alexion Pharmaceuticals, which manufactures and distributes the drug, as well as other pharmaceutical companies that produce generic versions of the drug. Additionally, there are a number of specialty pharmacies that provide access to Soliris for patients who cannot afford the high cost of the drug. Show Less Read more